Template:Ergotamine: Difference between revisions

Jump to navigation Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...")
 
No edit summary
Line 3: Line 3:
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ERGOMAR (ergotamine tartrate) tablet<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ERGOMAR (ergotamine tartrate) tablet<sup>®</sup> FDA Package Insert
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine dosage forms and strengths|Dosage Forms and Strengths]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine contraindications|Contraindications]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine warnings and precautions|Warnings and Precautions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine patient counseling information|Patient Counseling Information]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Ergotamine
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ergotamine|{{fontcolor|#6C7B8B|Ergotamine}}]]'''''
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | medihaler ergotamine (ergotamine tartrate)  aerosol, metered  [3M Riker] <sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]]

Revision as of 02:23, 11 February 2014